Indian Journal of Psychiatry · 2014 · 11 citations · 7 references
MedicinePharmacologyPsychiatryClinical PharmacologyNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDopaminergic PharmacologySchizophrenia PharmacotherapySerotonergic PharmacologyAntipsychotic ActionAntipsychotic Medication UseAntipsychotic Side EffectsAntipsychotic-induced AkathisiaAtypical Antipsychotic TreatmentNegative Symptom TreatmentSerotonergic NeurotransmissionSide Effect Profile
Amisulpride, the newly introduced antipsychotic in India, is claimed to be effective in both positive and negative symptom schizophrenia and related disorders, though it has little or no action on serotonergic receptors. Limbic selectivity and lower striatal dopaminergic receptor binding capacity causes very low incidence of EPS. But, in clinical practice, we are getting EPS with this drug even at lower doses. We have reported three cases of akathisia, acute dystonia, and drug-induced Parkinsonism with low doses of amisulpride. So, we should keep this side effect in mind when using amisulpride. In fact, more studies are required in our country to find out the incidence of EPS and other associated mechanism.
7
H. Schoemaker, Y. Claustre, Dominique Fage et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 374 citations · Full text
Ghislaine Perrault, Ronan Depoortère, Eliane Morel et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 233 citations
Rodrigo A. Bressan, Kjell Erlandsson, Hugh Jones et al. · American Journal of Psychiatry · 2003 · 109 citations
Medicine, Pharmacology, Psychiatry +16
Amisulpride versus Amineptine and Placebo for the Treatment of Dysthymia
P Boyer, Y. Lecrubier, Aline Stalla‐Bourdillon et al. · Neuropsychobiology · 1999 · 103 citations